MAP2K7 and metastatic melanoma: Particularly in newly diagnosed, symptomatic, LDH-high metastatic melanoma, prompt treatment initiation with BRAF/MEK inhibition allows for a rapid tumor and clinical response in patients harboring mBRAF.